Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 14, 2008. The report details a specific corporate action regarding the company's share capital rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,194.9791 pence per share.
Material Changes
The primary material change reported is the execution of a share buyback program authorized by shareholders at the Annual General Meeting on May 21, 2008. On July 14, 2008, GSK purchased and cancelled 2,698,000 Ordinary shares. Following this transaction:
- Treasury shares held by the Company total 474,194,158, representing 9.01% of total voting rights.
- Shares in issue (excluding Treasury shares) stand at 5,261,683,063.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It strictly serves as a notification of the share cancellation in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,261,683,063) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.01%).
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.